Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation

Inclusion Criteria: * Male or female of nonchildbearing potential. * Healthy subjects. Exclusion Criteria: * Evidence of coagulation disturbances, or disposition for thrombo-embolic events * Liver function tests more than 1.2 times the upper normal limits * Participants with thyroid disorders as evidenced by assessment of TSH levels outside the normal reference range at screening. * Prior history of thromboembolic complications including those in first degree relatives. * Glomerular filtration rate (GFR) is lower than estimated GFR 62 mL/min/1.73 m2 using the Modification of Diet in Renal Disease Study equation. * Anaphylactic or systemic reactions to human plasma, plasma products, or blood products. * History of hypersensitivity to active or inactive excipients of VKA * Gastrointestinal disease that may impair VKA absorption.. * Participation in another clinical study \<30 days prior to study entry. * Any clinically significant history of or current clinically significant disease or disorder as judged by the Investigator. * Positive nasopharyngeal PCR test for SARS-CoV-2 on Day -11 or Day -1. * Positive pregnancy test at screening, Day -11, or Day -1.